Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging: ow.ly/KBsY50ZZGQ3 #Aging

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference: ow.ly/iM7q50ZKCLi #GeneTherapy #LungCancer #Diabetes

$GNPX has treated 100+ patients with Reqorsa® throughout its various clinical trials. While other cancer treatments can cause harsh side effects and have long-term effects, we believe in REQORSA’s high degree of patient safety and tolerability #LungCancer

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy: ow.ly/X8cq50ZATey #Diabetes #GeneTherapy

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies: ow.ly/YY5m50ZvMn7 #LungCancer

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer: ow.ly/9Bj150ZfcY9 #LungCancer #GeneTherapy

Genprex to Participate at BIO International Convention 2026: ow.ly/WLjg50ZcIk6 #BIO2026 #GeneTherapy #LungCancer #Diabetes

A few members from the Genprex team attended #ASCO2026 this week where our collaborators' abstract was published detailing positive clinical data from studies of predictive biomarkers in patients receiving Reqorsa® for the treatment of #lungcancer.

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting: ow.ly/mlEW50Z4bQs #ASCO #LungCancer

Our research collaborators presented positive preclinical data on our diabetes gene therapy at the 2026 ASGCT Annual Meeting. The poster can be reviewed in detail by clicking here: ow.ly/5to850Z0ee2 #Diabetes #Type2 #GeneTherapy

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: ow.ly/uQlx50YZtGn #GeneTherapy #Diabetes

Genprex was featured in Cure's Member Spotlight series, where they highlight the groundbreaking work of the companies and individuals in Cure’s community. Check out the Q&A with Genprex's President and CEO here: ow.ly/ByIR50YZ0Ns #GeneTherapy #LungCancer #Diabetes

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer: ow.ly/irx250YSoy9 #GeneTherapy #LungCancer

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: ow.ly/hizI50YR0Ly #Diabetes #GeneTherapy

Genprex collaborators presented preclinical data at #AACR26 in a poster, titled, "Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro." To view the poster, click here: ow.ly/cPHL50YNAi3 #GeneTherapy $GNPX

$GNPX Collaborators presented preclinical data on Reqorsa Gene Therapy in EML4-ALK bearing NSCLC at #AARC26. Read the poster in more detail here: ow.ly/fIJb50YNAbS #LungCancer #GeneTherapy

$GNPX's Chief Medical Officer, Mark Berger, MD, poses with one of our collaborators at the #AACR26 conference. To view the poster, "TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy" in more detail, click here: ow.ly/Z1ol50YNA2l #LungCancer

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting: ow.ly/eQgk50YNUgU #LungCancer #GeneTherapy

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy: genprex.com/2026/04/21/genpr… #lungcancer #tailoredtreatment #genetherapy

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: ow.ly/10Nl50YMtk6 #AACR #LungCancer #GeneTherapy #Oncology